Dalmane advertisement.

[s.l.]: [s.n.], 1972

Dalmane® (flurazepam HCl)

One 30-mg capsule h.s.—recommended adult dosage.
One 15-mg capsule h.s.—initial dosage for elderly or debilitated patients.

Relatively safe, as reported clinically

Morning "hang-over" has been relatively infrequent and instances of paradoxical reactions (excitement) and hypotension have been rare. Dizziness, drowsiness, lightheadedness, and the like, were the side effects noted most frequently with Dalmane, particularly in the elderly or debilitated.

*Survey by professional publication—data on file and available on request.

References: 1. Data on file, Medical Department, Hoffmann-La Roche Inc., Nutley, New Jersey. **2.** Meyer, J. A.: "Flurazepam Hydrochloride for the Short-Term Treatment of Insomnia in the Hospitalized Post-Surgical Patient," Scientific Exhibit presented at AAGP, San Francisco, Calif., Sept. 28–Oct. 1, 1970.

For important considerations in the administration of Dalmane (flurazepam HCl), please see Complete Product Information, a summary of which follows:

Indications: Effective in all types of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening; in patients with recurring insomnia or poor sleeping habits; and in acute or chronic medical situations requiring restful sleep. Since insomnia is often transient and intermittent, prolonged administration is generally not necessary or recommended.

Contraindications: Known hypersensitivity to flurazepam HCl.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. Caution against hazardous occupations requiring complete mental alertness (*e.g.,* operating machinery, driving). Use in women who are or may become pregnant only when potential benefits have been weighed against possible hazards. Not recommended for use in persons under 15 years of age. Though physical and psychological dependence have not been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage.

Precautions: In elderly and debilitated, initial dosage should be limited to 15 mg to preclude oversedation, dizziness and/or ataxia. If combined with other drugs having hypnotic or CNS-depressant effects, consider potential additive effects. Employ usual precautions in patients who are severely depressed, or with latent depression or suicidal tendencies. Periodic blood counts and liver and kidney function tests are advised during repeated therapy. Observe usual precautions in presence of impaired renal or hepatic function.

Adverse Reactions: Dizziness, drowsiness, lightheadedness, staggering, ataxia and falling have occurred, particularly in elderly or debilitated patients. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdosage, have been reported. Also reported were headache, heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, GI pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains and GU complaints. There have also been rare occurrences of sweating, flushes, difficulty in focusing, blurred vision, burning eyes, faintness, hypotension, shortness of breath, pruritus, skin rash, dry mouth, bitter taste, excessive salivation, anorexia, euphoria, depression, slurred speech, confusion, restlessness, hallucinations and elevated SGOT, SGPT, total and direct bilirubins and alkaline phosphatase. Paradoxical reactions, *e.g.,* excitement, stimulation and hyperactivity, have also been reported in rare instances.

Supplied: Capsules containing 15 mg or 30 mg flurazepam HCl.

ROCHE

Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110